依折麦布在分子水平治疗冠心病并发糖尿病的进展  

Progress of ezetimibe in molecular-level treatment of coronary heart disease complicated with diabetes

作　　者：丁玲玲[1] 吴晓羽[1] 

机构地区：[1]哈尔滨医科大学第一附属医院心血管内科,黑龙江哈尔滨150001

出　　处：《心脏杂志》2016年第6期736-740,共5页Chinese Heart Journal

基　　金：黑龙江省自然基金项目资助(D201058);哈尔滨市科技局项目资助(2012RFXXS056)

摘　　要：尼曼-皮克C1型类似蛋白(NPC1L)1在依折麦布降脂治疗中起到举足轻重的作用。同时依折麦布可以降低血清二肽基肽酶(DPP)-4活性和增加血清活性胰高血糖素样肽(GLP)-1水平,在糖尿病患者中对血糖可以进行一定程度的控制。临床研究表明,依折麦布具有降脂,预防冠心病,降低心血管发病率,尤其是应用在冠心病并发糖尿病患者中。近年来人们对NPC1L1、DPP-4和GLP-1在冠心病并发糖尿病患者中的作用有了更深一步的研究。Niemann-Pick C1 Like 1 （NPC1L1） plays a decisive role in ezetimibe in lipid-lowering therapy. Ezetimibe can reduce serum dipeptidyl peptidase 4 （ DPP-4 ） activity and increase the activity of serum glucagon-like peptide 1 （ GLP-1 ）, thus controlling blood glucose to a certain degree in diabetic patients. Clinical studies have shown that ezetimibe can lower lipid levels, prevent coronary heart disease （CHD） and reduce the incidence of cardiovascular diseases, especially in patients with CHD complicated with diabetes. In recent years, more in-depth research has been conducted concerning the roles of NPC1L1, GLP-1 and DPP-4 in patients with CHD complicated with diabetes.

关 键 词：依折麦布 尼曼-皮克C1型类似蛋白1 胰高血糖素样肽-1 二肽基肽酶-4 

分 类 号：R543.5[医药卫生—心血管疾病]